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Articles
Oral doxycycline for the prevention of postoperative 
trachomatous trichiasis in Ethiopia: a randomised, 
double-blind, placebo-controlled trial
Esmael Habtamu, Tariku Wondie, Sintayehu Aweke, Zerihun Tadesse, Mulat Zerihun, Bizuayehu Gashaw, Chrissy H Roberts, Amir Bedri Kello, 
David C W Mabey, Saul N Rajak, E Kelly Callahan, David Macleod, Helen A Weiss, Matthew J Burton
Summary
Background Trachomatous trichiasis is treated surgically to prevent sight loss. Unfavourable surgical outcomes remain 
a major challenge. We investigated the hypothesis that doxycycline might reduce the risk of postoperative trichiasis 
following surgery in patients with trachomatous trichiasis through anti-matrix metalloproteinase and anti-inflammatory 
activity.
Methods In this randomised, double-blind, placebo-controlled trial, adults (aged >18 years) with upper lid 
trachomatous trichiasis in association with tarsal conjunctive scarring were recruited through community-based 
screening and surgical outreach campaigns in Ethiopia. Individuals who had previously had eyelid surgery were 
excluded. Participants were randomly assigned (1:1), with random block sizes of four or six, to receive oral doxycycline 
(100 mg once a day) or placebo for 28 days immediately after trichiasis surgery. Randomisation was stratified by 
surgeon. Patients, investigators, surgeons, and all other study team members were masked to study group allocation 
and treatment. Participants were examined at 10 days, and 1, 6, and 12 months after surgery. The primary outcome 
was the cumulative proportion of individuals who developed postoperative trichiasis by 12 months. Primary analyses 
were done in all participants who attended at least one of the four follow-up assessments. Safety analyses were done 
in all participants who attended either the 10 day or 1 month follow-up assessments. This trial is registered with the 
Pan African Clinical Trials Registry, number PACTR201512001370307.
Findings Between Dec 21, 2015, and April 6, 2016, 1000 patients with trichiasis were enrolled and randomly assigned to 
treatment (499 patients to doxycycline, 501 patients to placebo). All but one participant attended at least one follow-up 
assessment. Thus, 999 participants were assessed for the primary outcome: 498 in the doxycycline group and 501 in the 
placebo group. By month 12, 58 (12%) of 498 patients in the doxycycline group and 62 (12%) of 501 patients in the placebo 
group had developed postoperative trichiasis (adjusted odds ratio 0·91, 95% CI 0·61 to 1·34, p=0·63), with a risk 
difference of –0·5% (–4·5% to 3·5%). Significantly more patients in the doxycycline group had an adverse event than in 
the placebo group (18 [4%] of 498 vs six [1%] of 501; odds ratio 3·09, 95% CI 1·21–7·84; p=0·02). The most frequent 
adverse events in the doxycycline group were gastritis symptoms (n=9), constipation (n=4), and diarrhoea (n=4).
Interpretation Doxycycline did not reduce the risk of postoperative trichiasis and is therefore not indicated for the 
improvement of outcomes following trachomatous trichiasis surgery. Surgical programmes should continue to make 
efforts to strengthen surgical training and supervision to improve outcomes.
Funding The Wellcome Trust.
Copyright ©The author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Trachoma is a leading infectious cause of blindness 
worldwide. The neglected tropical disease is caused by 
Chlamydia trachomatis. Recurrent C trachomatis infections 
cause chronic inflammation and conjunctival scarring. 
The eyelids turn inwards and eyelashes scratch the surface 
of the eye (trachomatous trichiasis), leading to sight 
loss due to corneal opacification. Globally, an estimated 
1·9 million people are visually impaired, of whom 
0·45 million have irreversible blindness caused by 
trachoma.1 About 3·2 million people are estimated to 
have untreated trachomatous trichiasis and are thus at 
considerable risk of sight loss.2 The WHO Alliance for the 
Global Elimination of Trachoma by 20203 recommends the 
SAFE Strategy for trachoma control,4 which consists of 
surgery for trachomatous trichiasis, annual mass antibiotic 
treatment with azithromycin, and facial cleanliness and 
environ mental improvement strategies to suppress 
transmission.
Unfavourable outcomes after trichiasis surgery are a 
considerable concern for trachoma control programmes, 
and are reported to occur in around a third of patients. The 
most common adverse postoperative outcomes include 
postoperative trichiasis (about 20% of patients), eyelid 
contour abnormalities (around 10% of patients), and 
conjunctival granulomas (about 5% of patients).5–9 
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Postoperative trichiasis can lead to vision loss and pain and 
has the potential to undermine elimination efforts. On the 
basis of current clinical practice more than 54 000 patients 
who have surgery for trichiasis develop trachomatous 
trichiasis annually.1 The leading factors reported to 
contribute to the development of postoperative trichiasis 
include type of surgical procedure, surgeon skill, severity 
of preoperative disease, patient age, and ongoing con­
junctival inflammation and scarring.5–8,10,11
Conjunctival inflammation is frequently observed in 
people with trichiasis.10,12–18 The drivers of this persistent 
inflammation in individuals with scarring and trichiasis 
have not been fully elucidated; however, it is rarely 
associated with C trachomatis infection.16,19 Chronic 
conjunctival inflammation is associated with progressive 
conjunctival scarring.20 Studies16 in Ethiopia and Tanzania 
found that chronic conjunctival inflammation in tracho­
matous scarring was associated with the expression of 
proinflammatory cytokines. Conjunctival scarring was 
also associated with increased conjunctival expression of 
matrix metalloproteinases (MMPs), such as MMP­7, 
MMP­9, and MMP­12.21 MMPs degrade the extracellular 
matrix, promote inflammatory cell infiltration, and 
facilitate tissue remodelling and scar formation. In our 
previous studies,22,23 following trichiasis surgery, patients 
had altered expression of several pro­inflammatory 
cytokines and MMPs, which could favour postoperative 
scarring. In other types of conjunctival surgery 
(eg, trabeculectomy for glaucoma), poor outcomes occur 
because of excessive inflammation and fibrosis during 
initial wound healing, which is mediated by fibroblast 
and MMP activity. Similar alterations in wound healing 
processes are likely to occur following trichiasis surgery 
and might contribute to the development of postoperative 
trichiasis and eyelid contour abnormalities.
To reduce early postoperative trachomatous trichiasis 
due to contractile scarring it might be beneficial to inhibit 
MMP and inflammatory cytokine activity. However, at 
present, interventions used in other types of ophthalmic 
surgery (ie, mitomycin and fluorouracil) would not be 
suitable for patients who have surgery for trachomatous 
trichiasis because of their toxicity, specific handling 
requirements, and high cost. Doxycycline is a widely 
available, broad­spectrum, tetracycline­based antibiotic 
that is effective against C trachomatis, and also has anti­
inflammatory and anti­MMP properties.24 Doxycycline 
inhibits MMP activity via several mechanisms: reduced 
MMP expression, blocking pro­MMP activation, and direct 
inhibition by binding Zn²+ and Ca²+ ions at the catalytic 
site.24 An in­vitro study25 examined collagen matrix 
contraction in tarsal conjunctival fibroblasts cultured from 
biopsy samples of individuals who had trichiasis surgery. 
The expression of MMP­1, MMP­2, MMP­7, MMP­9, and 
MMP­12 was significantly higher during the contraction 
assay than at baseline. The addition of doxycycline reduced 
collagen gel contraction by up to 75%, with no evidence of 
toxicity. MMP production was significantly reduced by the 
doxycycline treatment. An ex­vivo study26 investigating the 
inhibitory effects of doxycycline on MMP­9 in brain 
arteriovenous malformations showed that doxycycline 
significantly decreases MMP­9 concentrations.
Doxycycline has been widely used in various clinical 
situations because of its putative anti­inflammatory 
and anti­scarring properties, mediated via the inhibition 
of MMPs and inflammatory cytokines, including perio­
dontitis, pulmonary fibrosis, and vascular disorders, and 
Research in context
Evidence before this study
Doxycycline has been widely used in various clinical situations for 
its putative anti-inflammatory and anti-scarring properties. In the 
first weeks after trachomatous trichiasis surgery, progressive 
conjunctival inflammation and contractile scarring mediated by 
matrix metalloproteinase and inflammatory cytokine activity 
might lead to unfavourable outcomes. On Sept 13, 2017, 
we updated a search done for a published Cochrane Collaboration 
systematic review of the management of trachomatous trichiasis 
(Burton and colleagues, 2015). We searched CENTRAL, Ovid 
MEDLINE, Embase, the International Clinical Trials Registry 
Platform, ClinicalTrials.gov, and WHO International Clinical Trials 
Registry Platform using the search terms “trachoma” and 
“trichiasis”. Full search methods for each database are available in 
the Cochrane review’s appendix. We found no studies examining 
the effect of doxycycline on trichiasis surgery outcomes.
Added value of this study
To the best of our knowledge this is the first trial investigating 
the use of doxycycline to improve outcomes following trichiasis 
surgery. Our trial was done to investigate whether oral 
doxycycline might improve trachomatous trichiasis surgery 
outcomes by suppressing progressive inflammation and 
contractile scarring during the surgical wound healing process. 
The results show that oral doxycycline does not improve surgical 
outcomes following trichiasis surgery, and does not affect the 
extent of postoperative conjunctival scarring or conjunctival 
inflammation, whether this is related to the initial wound 
healing process or longer-term chronic progression.
Implications of all the available evidence
This study provides evidence that oral doxycycline does not 
improve outcomes in trachomatous trichiasis surgery, and 
therefore should not be indicated for this purpose. Consistent 
with previous studies, our study showed that other factors, such 
as preoperative disease severity, surgeon skill, and patient age 
are important determinants of outcome, suggesting that 
trachoma control programmes should focus on addressing 
these factors and continue to make efforts to improve surgical 
training and supervision. Further studies are required to 
investigate the association between postoperative scarring and 
trichiasis surgery outcomes.
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in ophthalmology for treating ocular surface disorders, 
such as ocular rosacea, severe microbial keratitis, alkali 
injuries, and recurrent corneal erosion syndrome.27–34 
Doxycycline is considered a safe drug, and has been 
tested in a community­wide treatment study of oncho­
cerciasis,35,36 in which patient adherence was high (97%) and 
no serious side­effects were reported.
In view of the unfavourable outcomes following surgery 
in patients with trachomatous trichiasis and the 
anti­MMP and anti­inflammatory properties of doxycyline, 
we hypothesised that doxycycline might improve surgical 
outcomes. The aim of our trial was to determine whether 
oral doxycycline can reduce the risk of postoperative 
trichiasis and eyelid contour abnormalities following 
surgery in patients with trachomatous trichiasis.
Methods
Study design and participants
We did a double­blind, randomised, placebo­controlled 
trial in Ethiopia. Participants were mainly recruited 
through community­based screening by a mobile eye 
care team and by organising community­based surgical 
outreach campaigns in various health facilities across 
five districts of the West Gojam Zone in the Amhara 
Region.
Eligible participants (aged >18 years) had upper lid 
trachomatous trichiasis (one or more eyelashes touching 
the eye or evidence of epilation) with tarsal conjunctival 
scarring. We excluded people who had previously had 
eyelid surgery, individuals with trichiasis resulting from 
other eyelid pathologies, and people with contra in­
dications to doxycycline use, including renal or liver 
impairment, myasthenia gravis, and people taking 
warfarin, sulphonylureas, or doxycycline. Individuals 
with hypertension (blood pressure >170/110 mm Hg), 
known allergy to doxycycline or tetracycline, and pregnant 
or lactating women were also excluded. Written informed 
consent was obtained from all participants in Amharic 
before enrolment. Illiterate participants were read the 
information sheet and consent form, and their consent 
was recorded by thumbprint in the presence of a witness.
The study was approved by the Ethiopian National 
Health Research Ethics Review Committee, the London 
School of Hygiene & Tropical Medicine Ethics Committee, 
Emory University Institutional Review Board, and the 
Ethiopia Food, Medicine and Healthcare Administration 
and Controls Authority, and was done in accordance with 
the Declaration of Helsinki and International Conference 
on Harmonisation–Good Clinical Practice guidelines.
Randomisation and masking
Participants were randomly assigned (1:1) to receive either 
doxycycline or placebo once daily for 28 days, with a random 
block size of four or six. Randomisation was stratified by 
surgeon because of potential inter surgeon variability. An 
independent statistician was responsible for computerised 
sequence generation. The allocation sequences for each 
surgeon were concealed in sequentially numbered, sealed, 
opaque envelopes, which were prepared by a person 
independent of all other aspects of the trial.
After meeting inclusion criteria and completing 
baseline assessments, participants were allocated to the 
next available surgeon. On most recruitment days, two 
surgeons operated simultaneously. Immediately after 
surgery, patients were brought to the randomisation area 
by their surgeon and were assigned to a study group by a 
pharmacist who opened the next envelope in that 
surgeon’s sequence to determine allocation.
The patient, the two outcome assessors (EH and SA), 
the pharmacist, the surgeons, and all other study team 
members were masked to study group allocations 
and treatment. The doxycycline and placebo were 
produced as encapsulated medication by East African 
Pharmaceuticals (Addis Ababa, Ethiopia). The medication 
boxes, blister strips, and doxycycline and placebo 
capsules were identical in appearance.
Procedures
Participants’ demographic characteristics were recorded 
at the preoperative assessment before randomisation. 
Visual acuity at 2 m was assessed according to the 
logarithm of the minimum angle of resolution (logMAR) 
using PeekAcuity software (Peek Vision, London, UK) on 
a smartphone in a dark room.37 For visual acuities of 
counting fingers or less, logMAR values were assigned 
as follows: counting fingers, 2·0; hand movements, 2·5; 
perception of light, 3·0; and no perception of light, 3·5.17
Eyes were examined by a single examiner (EH) using 
2·5 × binocular loupes and a torch, and graded using a 
Detailed WHO (Follicles, Papillae, Cicatricae) Grading 
System.38 Eyelashes touching the eye were counted and 
subdivided by the part of the eye contacted (cornea, lateral, 
or medial conjunctiva). Trichiasis subtypes were defined 
as metaplastic, mis directed, and entropic.39 Clinical 
evidence of epilation was identified by broken or newly 
growing eyelashes, or areas of the eyelid without lashes. 
Entropion of the upper lid was graded according to the 
degree of eyelid margin inward rotation.39 Corneal 
scarring was graded using detailed criteria,40 based on an 
expansion of the WHO (Follicles, Papillae, Cicatricae) 
Grading System. Four standardised high­resolution 
digital photographs of trichiasis (in straight gaze and up 
gaze), the cornea, and tarsal conjunctiva were taken, 
using a Nikon D90 digital SLR camera with 105 mm 
macro lens and R1C1 flash units (Nikon, Tokyo, Japan).41
Before recruitment, we selected ten experienced 
trichiasis nurse­surgeons, who did posterior lamellar tarsal 
rotation (PLTR) surgery regularly within the Amhara 
Region trachoma control programme. The nurse­surgeons 
had refresher training, which was standardised by an 
experienced ophthalmologist using the WHO manual 
assessment procedure. The best six surgeons were chosen 
to do the surgery in the trial. Participants were treated 
surgically using PLTR, following the procedures described 
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in the WHO Trichiasis Surgery for Trachoma manual.42 
Postoperatively, operated eyes were padded for 1 day and 
tetracycline eye ointment 1% was self­administered twice a 
day for 2 weeks.
Immediately after trichiasis surgery, patients were 
randomly assigned to receive oral doxycycline 100 mg or 
placebo 100 mg for 28 days. Participants were examined 
at 10 days, 1 month, 6 months, and 12 months after 
surgery. On day 10, participants were examined for 
postoperative trichiasis and surgical complications 
before suture removal. At 1 month, 6 month, and 
12 month follow­up assessments, participants were 
re­examined (by SA at 1 month and 6 months and EH at 
12 months) and photographed following the same 
procedures used at baseline. The examiners (EH and SA) 
were standardised and had very strong agreement 
for the primary outcome in grading validation studies 
(κ=0·92). On the basis of severity, postoperative 
trichiasis was categorised as minor trichiasis (less than 
six eyelashes touching the eye, or evidence of epilation 
in less than a third of the eyelid margin) and major 
trichiasis (six or more eyelashes touching the eye, or 
evidence of epilation in a third or more of the eyelid 
margin). Individuals who had postoperative trichiasis at 
any follow­up assessment were offered epilation or 
repeat surgery by the most experienced surgeon in the 
area on the basis of severity using previously defined 
criteria.43 Grading of entropion correction, granuloma, 
and eyelid contour abnormalities was done according to 
previously described criteria.7 Participants with other 
ophthalmic pathologies were referred to the nearest 
eye unit.
At day 10 and 1 month follow­up assessments, partici­
pants were interviewed about drug adherence and 
adverse events. Drug adherence was assessed by asking 
participants whether they had stopped taking the 
treatment and by counting the number of capsules 
remaining. If the participant did not bring the medication 
box with them to the follow­up, a member of the study 
team visited the participant’s home to count the number 
of capsules remaining.
Outcomes
The primary outcome was the cumulative proportion of 
individuals who developed postoperative trichiasis by 
12 months (ie, patients diagnosed with postoperative 
trichiasis at any one of the four follow up visits within 
12 months of surgery). Postoperative trichiasis was 
defined as one or more eyelashes touching the eye or 
clinical evidence of epilation, or a history of repeat 
trichiasis surgery by 12 months.
A­priori defined secondary outcomes were: post­
operative trichiasis at 1 month, 6 months, and 12 months; 
3593 patients assessed for eligibility
1000  enrolled and randomly assigned
 2593 excluded
1422 had other ocular conditions
449 had no apparent ocular 
problem 
707 had trichiasis but did not 
meet inclusion criteria
15 declined surgery 
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499 assigned to doxycycline
2 not seen
1 died
1 moved away
 497 participants seen
7 not seen
1 died
1 travelled
1 moved away 
2 declined 
2 incomplete data 
492 participants seen
11 not seen
7 died
2 travelled
2 moved away
498 included in the modified
ITT analysis
  481 participants seen
18 not seen
4 died
5 travelled
6 moved away 
3 declined  
 488 participants seen
1 not analysed
1 died
501 assigned to placebo
2 not seen
2 incomplete data
499 participants seen
1 not seen
1 moved away
500 participants seen
7 not seen
3 died
2 travelled
2 moved away
501 included in the modified
ITT analysis
493 participants seen
8 not seen
2 died
1 travelled
4 moved away 
1 declined
 494 participants seen
0 not analysed
Figure: Trial profile
ITT=intention-to-treat.
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postoperative trichiasis difference by surgeon; post­
operative trichiasis difference by baseline disease severity; 
number, type, and location of postoperative eyelashes at 
12 months; eyelid contour abnormalities at 1 month, 
6 months, and 12 months; corneal opacity and vision 
changes at 12 months; postoperative surgical compli­
cations (infection and granulomas); and patient reported 
adverse events in the first month after surgery.
Statistical analysis
A previous randomised trial in Ethiopia17 of patients who 
had PLTR surgery reported a 1­year postoperative trichiasis 
risk of 18%. We estimated that a sample of 836 participants 
would be needed to detect a clinically significant difference 
in postoperative trichiasis (18% vs 10%) with 90% power. 
We aimed to recruit 1000 participants (500 per group), 
allowing for about 15% loss to follow­up.
For participants who had bilateral surgery, we randomly 
designated one eye as the study eye for the analysis. 
Analyses were by modified intention to treat, with primary 
outcome data analysed for all participants seen at any of 
the four follow­up assessments. Participants who did not 
attend at least one of the four follow­up assessments were 
excluded from the analysis. The effect of the intervention 
on the primary and binary secondary outcomes was 
analysed using logistic regression to estimate the odds 
ratio (OR) and 95% CI. Intervention effects on ordered 
categorical secondary outcomes (ie, changes in visual 
acuity and corneal opacity) were assessed using ordinal 
logistic regression. Effects on categorical secondary 
outcomes (ie, type and location of postoperative trichiasis 
eyelashes, eyelid contour abnormalities, and entropion 
correction) were assessed using multinomial logistic 
regression to estimate relative risk ratio and 95% CI. 
Negative binomial regression was used to analyse the 
difference in the number of postoperative lashes touching 
the eye between the two groups. A non­prespecified sign 
test was used to analyse the clinical significance of eyelid 
contour abnormalities improvement between 1 month 
and 6 months, 1 month and 12 months, and 6 months 
and 12 months in all participants. A multivariable 
logistic regression model was used to identify potential 
explanatory factors for postoperative trichiasis by 1 year, 
granuloma by 1 year, and eyelid contour abnormalities 
at 1 year, in all study participants regardless of inter vention 
allocation. All variables with a p value of less than 0·05 in 
the univariable model were included in the multivariable 
analysis and a likelihood ratio test was used to establish 
the variables for inclusion in the final multivariable 
logistic regression model at a p value of less than 0·20.
All comparisons between the two treatment groups were 
controlled for surgeon in the model to account for 
the stratified randomisation, and for preoperative disease 
severity. The risk difference in the primary outcome 
between the two groups was estimated. Effect modification 
between treatment group and a­priori defined factors such 
as surgeon, preoperative trichiasis severity, papillary 
Baseline 12 months
Placebo 
(n=501)
Doxycycline 
(n=499)
Placebo 
(n=494)
Doxycycline 
(n=488)
Sex
Women 365 (73%) 345 (69%) ·· ··
Men 136 (27%) 154 (31%) ·· ··
Age, years 49·9 (14·0) 52·1 (14·3) ·· ··
Illiterate 433 (86%) 449 (90%) ·· ··
Best corrected logMAR visual acuity in study eye
–0·1 to 0·3 139 (28%) 134 (27%) 192 (39%) 167 (34%)
0·3 to 0·7 231 (46%) 243 (49%) 212 (43%) 210 (43%)
0·7 to 1·1 101 (20%) 87 (17%) 67 (14%) 88 (18%)
1·1 to 2·0 7 (1%) 9 (2%) 3 (1%) 6 (1%)
CF/HM/PL 22 (4%) 25 (5%) 18 (4%) 16 (3%)
NPL 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%)
Not possible to measure ·· ·· 1 (<1%) ··
Entropion grade
0 1 (<1%) 0 447 (90%) 436 (89%)
1 21 (4%) 27 (5%) 33 (7%) 43 (9%)
2 415 (83%) 408 (82%) 14 (3%) 9 (2%)
3 57 (11%) 56 (11%) 0 0
4 7 (1%) 8 (2%) 0 0
Trichiasis (number of eyelashes)
No trichiasis ·· ·· 450 (90%) 441 (90%)
None (epilating) 25 (5%) 34 (7%) 4 (1%) 3 (1%)
1–5 292 (58%) 268 (54%) 39 (8%) 43 (9%)
6–9 96 (19%) 107 (21%) 0 1 (<1%)
10–19 68 (14%) 62 (12%) 0 0
≥20 20 (4%) 28 (6%) 1 (<1%) 0
Mean (SD)* 6·3 (6·8) 6·9 (8·0) 2·5 (3·9) 1·9 (1·4)
Epilation
Not epilating 229 (46%) 225 (45%) 484 (97%) 483 (99%)
Epilation in less than a third of 
eyelid margin
165 (33%) 162 (32%) 7 (1%) 4 (1%)
Epilation in a third or more of 
the eyelid margin
107 (21%) 112 (22%) 3 (1%) 1 (<1%)
Trichiasis severity
Minor 279 (56%) 244 (49%) 43 (9%) 45 (9%)
Major 222 (44%) 255 (51%) 1 (<1%) 2 (<1%)
Lash location
None (epilating) 25 (5%) 34 (7%) 4 (1%) 3 (1%)
Corneal only 406 (81%) 395 (79%) 28 (6%) 31 (6%)
Corneal and peripheral 62 (12%) 68 (14%) 5 (1%) 3 (1%)
Peripheral only 8 (2%) 2 (<1%) 7 (1%) 10 (2%)
Corneal opacity
None (CC0) 88 (18%) 94 (19%) 153 (31%) 163 (33%)
Peripheral (CC1) 174 (35%) 164 (33%) 115 (23%) 118 (24%)
Off centre faint (CC2a) 89 (18%) 112 (22%) 75 (15%) 77 (16%)
Off centre dense (CC2b) 10 (2%) 14 (3%) 9 (2%) 6 (1%)
Central faint (CC2c) 128 (26%) 91 (18%) 127 (26%) 108 (22%)
Central dense (CC2d) 12 (2%) 24 (5%) 12 (2%) 15 (3%)
Total central dense (CC3) 0 0 3 (1%) 1 (<1%)
Phthisis (CC4) 0 0 0 0
(Table 1 continues on next page)
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inflammation, age, and sex was investigated by including 
interaction terms in the model. Stratum specific ORs for 
the primary outcome were calculated with evidence of 
interaction with the intervention. A per­protocol analysis of 
the primary outcome was done using logistic regression for 
all participants who adhered to treatment. Participants 
were considered to have adhered to treatment if they 
reported at the 1 month follow­up that they had taken the 
allocated treatment without stopping for more than 1 day.
An independent data and safety monitoring committee 
oversaw the trial. Data were double­entered into 
Microsoft Access 2007 (Microsoft, Redmond, WA, USA) 
and transferred to Stata 11 (StataCorp, College Station, 
TX, USA) for analysis. This study is registered with 
the Pan African Clinical Trials Registry, number 
PACTR201512001370307.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Dec 21, 2015, and April 6, 2016, 3593 individuals 
were assessed for eligibility, of whom 1722 (48%) had 
trichiasis, 1422 (40%) had another ocular problem, 
and 449 (12%) had no ocular problems. Of the 
1722 individuals with trichiasis, 707 (41%) were ex cluded: 
344 (49%) had postoperative trichiasis, 175 (25%) had 
trichiasis with out clear tarsal conjunctival scarring, 
111 (16%) were lactating, 19 (3%) were pregnant, 
16 (2%) had high blood pressure, 12 (2%) had mental 
health or hearing problems, nine (1%) were younger than 
18 years, seven (1%) had kidney or liver problems, 
six (1%) were unable to attend follow­up, six (1%) were 
taking other multiple drugs, one (<1%) was taking 
doxycycline, and one (<1%) was seen after recruitment 
had been completed. Of the 1015 eligible participants, 
15 (1%) declined surgery. Thus, 1000 individuals with 
trichiasis were enrolled, and randomly assigned to receive 
doxycycline (499 patients) or placebo (501 patients; figure).
All but one participant in the doxycycline group attended 
at least one follow­up assessment. Thus, primary outcome 
data were available for 999 (100%) of 1000 trial participants: 
498 in the doxycycline group and 501 in the placebo group. 
Of the 992 participants seen at the 1 month follow­up 
(492 [99%] of 498 in the doxycycline group; 500 [100%] of 
501 in the placebo group), 815 (82%) participants had 
adhered to study treatment: 392 (48%) in the doxycycline 
group, and 423 (52%) in the placebo group (OR 0·71, 
95% CI 0·51–0·99, p=0·04). Adherence was similar 
between sexes (228 [80%] of 284 men vs 587 [83%] of 
708 women). However, older individuals (aged ≥60 years) 
were less likely to adhere to the study drug than younger 
individuals (OR 0·77, 95% CI 0·68–0·87, p<0·0001).
Baseline demographic and clinical characteristics 
were balanced between the two groups, with the 
exception of preoperative trichiasis severity (table 1). 
The mean age was 51·0 years (SD 14·1), and most 
participants were women (701 [70%]), and illiterate 
(881 [88%]). Clinical features, including visual acuity, 
corneal opacity, tarsal conjunctival scarring and 
inflammation, and entropion grade were similar across 
the two groups. The number and location of eyelashes 
touching the eye were balanced between the two groups. 
However, the proportion of participants with major 
trichiasis was higher in the doxycycline group than the 
placebo group (255 [51%] vs 222 [44%]) when extent 
of epilation was included in the trichiasis severity 
definition. 272 (54%) of 501 participants in the placebo 
group and 274 (55%) of 498 participants in the doxycline 
group had evidence of epilation. Of the 546 participants 
with epilation, 327 (60%) had epilation in less than a 
third of the eyelid (165 [33%] in the placebo group vs 
162 [32%] in the doxycycline group), and 219 (40%) 
had epilation in a third or more of the eyelid margin 
(107 [21%] vs 112 [22%]). 25 (5%) of 501 participants in 
the placebo group and 34 (7%) of 499 participants in the 
doxycycline group successfully epilated (no lashes 
touching).
By 12 months, postoperative trichiasis had developed in 
58 (12%) of 498 participants in the doxycycline group and 
Baseline 12 months
Placebo 
(n=501)
Doxycycline 
(n=499)
Placebo 
(n=494)
Doxycycline 
(n=488)
(Continued from previous page)
Tarsal conjunctiva inflammation
None (P0) 7 (1%) 9 (2%) 39 (8%) 48 (10%)
Mild (P1) 78 (16%) 87 (17%) 235 (48%) 224 (46%)
Moderate (P2) 278 (55%) 288 (58%) 197 (40%) 189 (39%)
Severe (P3) 138 (28%) 115 (23%) 23 (5%) 27 (6%)
Tarsal conjunctival scarring at baseline
None (C0) 0 0 ·· ··
Mild (C1) 15 (3%) 22 (4%) ·· ··
Moderate (C2) 405 (81%) 405 (81%) ·· ··
Severe (C3) 81 (16%) 72 (14%) ·· ··
Tarsal conjunctival scarring at 12 months
None (SC0) ·· ·· 0 0
Surgical line only (SC1) ·· ·· 0 0
Scattered scar (SC2) ·· ·· 2 (<1%) 4 (1%)
Widespread scar (SC3) ·· ·· 360 (73%) 321 (66%)
Widespread scar and distortion 
from surgery (SC4)
·· ·· 121 (24%) 155 (32%)
Widespread scar and distortion 
from scar (SC5)
·· ·· 11 (2%) 8 (2%)
Data are n (%), or mean (SD). logMAR=logarithm of the minimum angle of resolution. CF=counting fingers. 
HM=hand motion. PL=perception of light. NPL=no perception of light. *Excluding participants with no eyelashes 
touching the eyeball.
Table 1: Baseline and 12 month characteristics of participants 
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61 (12%) of 501 participants in the placebo group 
(adjusted OR 0·91, 95% CI 0·61 to 1·34, p=0·63). The 
risk difference for postoperative trichiasis between the 
doxycycline and placebo groups was –0·5% (95% CI 
–4·5% to 3·5%). When testing for effect modification 
using prespecified variables, results indicated that the 
intervention effect was modified by sex (pinteraction=0·02); 
however, the stratified estimates indicated that 
doxycycline did not affect the risk of postoperative 
trichiasis in women (OR 0·67, 95% CI 0·42–1·07, 
p=0·10) or men (OR 1·90, 0·88–4·11, p=0·10).
A per­protocol analysis of the primary outcome, 
adjusted for surgeon and triachiasis severity, found no 
difference in the cumulative risk by treatment group: 
Placebo Doxycycline OR (95% CI) p value
Cumulative proportion of patients with postoperative trichiasis* 61/501 (12%) 58/498 (12%) 0·91 (0·61–1·34) 0·63
Postoperative trachomatous trichiasis at 10 days* 3/499 (1%) 1/497 (<1%) 0·33 (0·03–3·2) 0·34
Postoperative trachomatous trichiasis at 1 month* 9/500 (2%) 5/492 (1%) 0·55 (0·18–1·7) 0·29
Postoperative trachomatous trichiasis at 6 months* 32/493 (6%) 29/481 (6%) 0·86 (0·50–1·46) 0·57
Postoperative trachomatous trichiasis at 12 months* 45/494 (9%) 47/492 (10%) 1·01 (0·65–1·57) 0·97
Cumulative postoperative trichiasis by baseline trichiasis severity†
Minor trachomatous trichiasis 20/279 (7%) 23/244 (9%) 1·41 (0·74–2·66) 0·29
Major trachomatous trichiasis 41/222 (18%) 35/254 (14%) 0·72 (0·43–1·19) 0·20
Cumulative postoperative trichiasis by baseline entropion severity†
None or mild 0 4/27 (15%) ·· ··
Moderate 48/415 (12%) 46/408 (11%) 0·97 (0·63–1·51) 0·91
Severe 13/64 (20%) 8/63 (13%) 0·63 (0·24–1·67) 0·35
Number of postoperative trichiasis eyelashes at 12 months 
(mean, SD)‡
2·5 (3·9) 1·9 (1·4) 0·85§ (0·58–1·25) 0·42
Location of postoperative trichiasis eyelashes at 12 months¶
None (epilating) 4/44 (9%) 3/47 (6%) 0·59|| (0·11–3·21) 0·57
Corneal 28/44 (64%) 31/47 (66%) 1 ··
Corneal and peripheral 5/44 (11%) 3/47 (6%) 0·37|| (0·07–1·94) 0·24
Peripheral 7/44 (16%) 10/47 (21%) 0·92|| (0·27–3·18) 0·90
Postoperative trichiasis by surgeon**
1 7/99 (7%) 8/102 (8%) 1·15 (0·40–3·31) 0·80
2 17/99 (17%) 13/97 (13%) 0·79 (0·35–1·78) 0·57
3 5/101 (5%) 11/99 (11%) 2·21 (0·73–6·70) 0·16
4 15/99 (15%) 16/98 (16%) 1·00 (0·45–2·19) 0·10
5†† 1/2 (50%) 1/2 (50%) 1·00 (0·02–50·4) 1·00
6 16/101 (16%) 9/100 (9%) 0·52 (0·22–1·23) 0·14
Eyelid contour abnormalities at 1 month¶
None (base outcome) 321/500 (64%) 311/492 (63%) 1 ··
Clinically non-significant (mild) 107/500 (21%) 108/492 (22%) 1·04|| (0·76–1·42) 0·80
Clinically significant (moderate and severe) 72/500 (14%) 73/492 (15%) 1·03|| (0·72–1·48) 0·87
Eyelid contour abnormalities at 6 months¶
None (base outcome) 411/493 (83%) 393/481 (82%) 1 ··
Clinically non-significant (mild) 46/493 (9%) 55/481 (11%) 1·25|| (0·83–1·90) 0·76
Clinically significant (moderate and severe) 36/493 (7%) 33/481 (7%) 0·94|| (0·57–1·54) 0·81
Eyelid contour abnormality at 12 months¶
None (base outcome) 439/494 (89%) 422/488 (86%) 1 ··
Clinically non-significant (mild) 35/494 (7%) 37/488 (8%) 1·08|| (0·66–1·75) 0·76
Clinically significant (moderate and severe) 20/494 (4%) 29/488 (6%) 1·47|| (0·81–2·65) 0·20
Granuloma by 12 months* 58/501 (12%) 51/498 (10%) 0·87 (0·58–1·30) 0·49
Sign of infection at 7–14 days‡‡ 41/499 (9%) 39/497 (8%) 0·94 (0·59–1·49) 0·79
Tarsal conjunctiva inflammation at 1 month§§ ·· ·· 0·88 (0·69–1·11) 0·23
None (P0) 4/500 (1%) 3/492 (1%) ·· ··
Mild (P1) 196/500 (39%) 210/492 (43%) ·· ··
Moderate (P2) 240/500 (48%) 228/492 (46%) ·· ··
Severe (P3) 60/500 (12%) 51/492 (11%) ·· ··
(Table 2 continues on next page)
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47 (12%) of 392 participants in the doxycycline group 
and 51 (12%) of 423 participants in the placebo group 
developed postoperative trichiasis by 12 months 
(OR 1·00, 95% CI 0·65–1·53, p=0·99). Evidence of effect 
modification by sex was found (pinteraction=0·01), and men 
in the doxycycline group were found to have an increased 
risk of postoperative trichiasis compared with men in the 
placebo group, but this association was weak (OR 2·31, 
95% CI 0·99–5·40, p=0·054). However, no significant 
differences in risk of postoperative triachisis were 
identified between women in the doxycycline and placebo 
groups (OR 0·66, 95% CI 0·39–1·11, p=0·12).
The proportion of participants with postoperative 
trichiasis was similar across the two groups at the 10 day 
follow­up, and 1, 6, and 12 month follow­up assessments 
(table 2). The cumulative risks of postoperative trichiasis in 
patients with major trichiasis and severe entropion were 
similar between the groups. No significant differences in 
the number or location of post operative trichiasis eyelashes 
were identified between the two treatment groups at 
12 months. The proportion of participants with granuloma 
by 12 months and eyelid contour abnormalities at 10 days, 
1 month, 6 months and 12 months was similar between 
treatment groups (table 2). No significant differences 
in visual acuity (p=0·88), corneal opacity (p=0·71), or 
entropion (p=0·39) were identified between the treatment 
groups at 12 months.
Eyelid contour abnormalities were more common at 
the 1 month follow­up than at the 6 month and 12 month 
follow­up assessments in both groups (table 2). Many 
participants with eyelid contour abnormalities at 1 month 
had statistically significant regression by 6 months 
(mild to none, 158 [77%] of 206 participants; moderate to 
mild or none, 86 [70%] of 122 participants; severe to mild 
or none, ten [48%] of 21 participants; sign test p<0·0001) 
and by 12 months (moderate to mild or none, 97 [79%] of 
123 participants; severe to mild or none, 11 [52%] of 
21 participants, sign test p<0·0001, table 3). Similar 
changes were also observed between the 6 month 
and 12 month follow­up assessments (mild to none, 
68 [67%] of 101 participants; moderate to mild or none, 
28 [44%] of 63 participants, sign test p<0·0001). However, 
no significant differences were identified between the 
doxycycline group and the placebo group (table 3). Of 
the 621 participants who did not have eyelid contour 
abnormalities at 1 month, 27 (4%) developed eyelid 
contour abnormalities by the 6 month follow­up and 
eight (1%) by the 12 month follow­up. Of the 797 partici­
pants without eyelid contour abnormalities at 6 months, 
12 (1·5%) had developed eyelid contour abnormalities by 
12 months. Of the 143 participants with clinically 
significant eyelid contour abnormalities at 1 month, 
47 (33%) still had clinically significant eyelid contour 
abnormalities at 6 months and 36 (25%) at 12 months 
(table 3).
Mild adverse events were reported by 18 (4%) of 
498 participants in the doxycycline group and six (1%) of 
501 participants in the placebo group (OR 3·09, 95% CI 
1·21–7·84, p=0·02; table 2). The five most frequent adverse 
events were gastritis symptoms (n=10 doxycycline group; 
n=1 placebo group), constipation (n=4 doxycycline group; 
n=2 placebo group), diarrhoea (n=4 doxycycline group; n=1 
placebo group), generalised weakness (n=3 doxycycline 
group; n=1 placebo group), and anorexia (n=3 doxycycline 
Placebo Doxycycline OR (95% CI) p value
(Continued from previous page)
Tarsal conjunctiva inflammation at 6 months§§ ·· ·· 0·84 (0·64–1·10) 0·21
None (P0) 1/493 (<1%) 4/481 (1%) ·· ··
Mild (P1) 332/493 (67%) 332/481 (69%) ·· ··
Moderate (P2) 143/493 (29%) 134/481 (28%) ·· ··
Severe (P3) 17/493 (3%) 11/481 (2%) ·· ··
Tarsal conjunctiva scarring at 6 months§§ ·· ·· 1·22 (0·85–1·77) 0·28 
None (SC0) ·· ·· ·· ··
Surgical line only (SC1) ·· ·· ·· ··
Scattered scar (SC2) 4/493 (1%) 3/481 (1%) ·· ··
Widespread scar (SC3) 431/493 (87%) 409/481 (85%) ·· ··
Widespread scar and distortion from surgery (SC4) 56/493 (11%) 66/481 (14%) ·· ··
Widespread scar and distortion from scar (SC5) 2/493 (<1%) 3/481 (1%) ·· ··
Adverse events¶¶ 6/501 (1%) 18/499 (4%) 3·09 (1·21–7·84) 0·02
Data are n/N (%), unless otherwise stated. OR=odds ratio. *Analysis done using logistic regression adjusted for surgeon and trichiasis severity at baseline. †Analysis done 
using logistic regression adjusted for surgeon to see the effect of the two surgical procedures on cumulative postoperative trichiasis (by 12 months) across baseline trichiasis 
and entropion severity level. ‡Analysis done using negative binomial regression adjusted for surgeon and trichiasis severity at baseline. §Incidence rate ratio. ¶Analysis done 
by multinomial logistic regression adjusted for surgeon and trichiasis severity at baseline. ||Relative risk ratio. **Analysis done by logistic regression adjusted for trichiasis 
severity at baseline. ††Surgeon 5 moved to another region of Ethiopia immediately after the start of the trial. ‡‡All patients had mild infections, which improved without 
further treatment. §§Analysis done by ordinal logistic regression adjusted for surgeon and trichiasis severity at baseline. ¶¶Analysis done by logistic regression.
Table 2: Primary and secondary clinical outcomes and changes in clinical phenotype
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group; n=1 placebo group). No treatment­related serious 
adverse events were reported.
We did univariable and multivariable analyses of factors 
associated with postoperative trichiasis by 12 months in 
all trial participants (table 4), which showed that older 
age, major trichiasis at baseline, peripheral eyelashes at 
baseline, surgeon, and postoperative under­correction 
independently predicted postoperative trichiasis, whereas 
eyelid contour abnormalities at 12 months were associated 
with a significantly lower risk of postoperative trichiasis.
The presence of eyelid contour abnormalities at 
12 months, irrespective of treatment group, was 
associated with increasing age (OR 1·46, 95% CI 
1·25–1·71, p<0·0001), major trichiasis at baseline 
(minor trichiasis, 51 [10%] of 516 patients vs major 
trichiasis, 70 [15%] of 466 patients; OR 1·47, 0·99–2·18, 
p=0·054), and surgeon (surgeon 4, 16 [8%] of 196 patients 
vs surgeon 6, 36 [19%] of 192 patients; OR 2·65, 
1·40–5·01, p=0·003). All other variables assessed were 
not associated with the presence of eyelid contour 
abnormalites (data not shown). The prevalence of 
granuloma during the 12 month period was associated 
with surgeon (surgeon 4, 13 [7%] of 197 patients vs 
surgeon 2, 31 [16%] of 196 patients; OR 2·59, 1·30–5·16, 
p=0·007), and eyelid contour abnormalities (no eyelid 
contour abnormalities, 81 [9%] of 861 patients vs eyelid 
contour abnormalities, 27 [22%] of 121 patients; OR 3·11, 
1·87–5·19, p<0·0001), whereas older age seemed to 
Patients with postoperative 
trachomatous trichiasis, 
n/N (%)
Univariable analysis Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
Sex 0·97 (0·63–1·48) 0·90 Not included Not included
Women 84/710 (12%) ·· ·· ·· ··
Men 35/289 (12%) ·· ·· ·· ··
Age, years 1·10 (0·96–1·27) 0·17* 1·21 (1·04–1·41) 0·01*
18–29 5/77 (6%) ·· ·· ·· ··
30–39 12/124 (10%) ·· ·· ·· ··
40–49 25/206 (12%) ·· ·· ·· ··
50–59 35/262 (13%) ·· ·· ·· ··
60–69 32/238 (13%) ·· ·· ·· ··
≥70 10/92 (11%) ·· ·· ·· ··
Treatment group 0·95 (0·65–1·39) 0·80 0·91 (0·60–1·37) 0·91
Placebo 61/501 (12%) ·· ·· ·· ··
Doxycycline 58/498 (12%) ·· ·· ·· ··
Trichiasis severity at baseline 2·12 (1·43–3·15) 0·0002 2·20 (1·44–3·36) 0·0003
Minor 43/523 (8%) ·· ·· ·· ··
Major 76/476 (16%) ·· ·· ·· ··
Entropion grade at baseline 1·52 (0·97–2·38) 0·07* Not included Not included
None or mild 4/49 (8%) ·· ·· ·· ··
Moderate 94/823 (11%) ·· ·· ·· ··
Severe 21/127 (17%) ·· ·· ·· ··
Eyelash location at baseline
Epilating 8/59 (14%) 1·30 (0·60–2·83) 0·51 1·56 (0·69–3·54) 0·29
Corneal 86/800 (11%) 1 (ref) ·· 1 (ref) ··
Corneal and peripheral 22/130 (17%) 1·69 (1·01–2·82) 0·04 1·47 (0·85–2·56) 0·17
Peripheral 3/10 (30%) 3·56 (0·90–14·0) 0·07 6·00 (1·33–26·92) 0·02
Papillary grade at baseline 0·97 (0·74–1·28) 0·83* Not included Not included
None 2/16 (13%) ·· ·· ·· ··
Mild 21/165 (13%) ·· ·· ·· ··
Moderate 66/566 (12%) ·· ·· ·· ··
Severe 30/252 (12%) ·· ·· ·· ··
Conjunctival scarring grade at baseline 1·07 (0·68–1·69) 0·76* Not included Not included
Mild 6/37 (16%) ·· ·· ·· ··
Moderate 92/810 (11%) ·· ·· ·· ··
Severe 21/152 (14%) ·· ·· ·· ··
(Table 4 continues on next page)
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have a protective effect (OR 0·88, 0·75–1·02, p=0·09). 
All other variables assessed were not associated with the 
prevalence of granuloma (data not shown).
Discussion
We tested the hypothesis that doxycycline could reduce 
the risk of postoperative trichiasis by reducing MMP and 
pro­inflammatory cytokine activity, thereby reducing 
inflammation and fibrosis during the initial wound 
healing stage. However, in this trial, we found no evidence 
to support this theory, with similar surgical outcomes 
observed between the doxycycline and placebo groups. 
To the best of our knowledge, this is the first study to 
have investigated the effect of doxycycline on surgical 
outcomes after trichiasis surgery. Although, fewer people 
in the doxycycline group adhered to study treatment 
than did those in the placebo group, per­protocol analysis 
found no difference in the risk of postoperative trichiasis 
between groups, when the analysis was restricted to 
participants who reported adherence at 1 month.
The rationale for this trial was that persistent 
conjunctival inflammation and progressive scarring after 
trichiasis surgery might contribute to the development 
of postoperative trichiasis. Several studies10,12,13,17,44,45 have 
found severe conjunctival inflammation before and after 
surgery is associated with postoperative trichiasis. Pre­
operatively, clinically visible conjunctival inflammation 
and scarring are associated with increased expression of 
pro­inflammatory cytokines (interleukin­1β, CXCL5, and 
S100A7) and MMPs (MMP­7, MMP­9 and MMP­12).16,21 
Similarly, increased expression of these factors has also 
been reported in patients following trichiasis surgery.23 
MMPs and pro­inflammatory cytokines are integral to 
wound healing and tissue remodelling processes, thus 
the excessive inflammation and profibrotic reaction in 
response to trichiasis surgery could plausibly result in 
poorer patient outcomes after surgery. Doxycycline has 
well characterised effects on these processes, suggesting 
potential benefit.
No differences in the severity of tarsal conjunctival 
scarring were found between the treatment groups at 
6 months or 12 months after surgery. Tarsal conjunctival 
scarring progresses gradually, increases with age, and is 
particularly associated with conjunctival inflammation.20 
It is possible that in some patients, scarring continues 
to progress after trichiasis surgery, contributing to post­
operative trichiasis. The results of our study indicate 
that 1 month of oral doxycycline treatment does not alter 
the degree of postoperative conjunctival scarring, whether 
this is associated with the initial wound healing process 
or longer­term chronic progression. Similarly, we did not 
observe a difference between treatment groups in the 
extent of clinically visible conjunctival inflammation 
1 month after surgery.
Patients with postoperative 
trachomatous trichiasis, 
n/N (%)
Univariable analysis Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
(Continued from previous page)
Surgeon
1 15/201 (7%) 1 (ref) ·· 1 (ref) ··
2 30/196 (15%) 2·24 (1·16–4·31) 0·02 2·36 (1·19–4·67) 0·01
3 16/200 (8%) 1·08 (0·52–2·24) 0·84 1·29 (0·60–2·73) 0·51
4 31/197 (16%) 2·32 (1·21–4·44) 0·01 2·02 (1·02–4·00) 0·04
5 2/4 (50%) 12·4 (1·63–94·3) 0·02 19·51 (1·99–191·5) 0·01
6 25/201 (12%) 1·76 (0·90–3·45) 0·10 1·87 (0·92–3·78) 0·08
Postoperative central correction at 12 months
Corrected 94/881 (11%) 1 (ref) ·· 1 (ref) ··
Over-corrected 2/50 (4%) 0·35 (0·08–1·46) 0·15 1·22 (0·19–7·96) 0·83
Under-corrected 23/51 (45%) 6·9 (3·81–12·4) <0·0001 6·97 (3·67–13·2) <0·0001
Papillary grade at 12 months 1·17 (0·90–1·53) 0·24* Not included Not included
None 3/87 (3%) ·· ·· ·· ··
Mild 63/459 (14%) ·· ·· ·· ··
Moderate 46/386 (12%) ·· ·· ·· ··
Severe 7/50 (14%) ·· ·· ·· ··
Eyelid contour abnormalities at 12 months 0·22 (0·08–0·61) 0·004 0·18 (0·05–0·68) 0·01
No 57/371 (15%) ·· ·· ·· ··
Yes 6/120 (5%) ·· ·· ·· ··
Analysis was done by logistic regression. Age (known risk factor for postoperative trichiasis) was included in the multivariable model regardless of significance in univariable 
analysis. Likelihood ratio test was done to determine the variables for inclusion in the final multivariable model. OR=odds ratio. *p value for trend.
Table 4: Univariable and multivariable associations between clinical and demographic factors and postoperative trichiasis by 12 months
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The risk of postoperative trichiasis 1 year after PLTR 
surgery was relatively low (12% in both groups). These 
results were similar to those previously reported for PLTR 
surgery (13%),7 suggesting consistent performance of this 
procedure in this context. This risk was lower than 
anticipated in the power calculation. However, our study 
had sufficient power to detect a halving of the postoperative 
trichiasis risk from 12% to 6%. Some evidence indicated 
that the intervention effect might be modified by sex; 
however, stratum­specific estimates did not support this 
finding. However, because the study was not powered to 
detect a difference within these strata we cannot make 
robust conclusions about the absence of an effect. In this 
study, the main determinants of postoperative trichiasis 
were pre operative trichiasis severity (major trachomatous 
trichiasis), peripheral trichiasis eyelash location, inter­
surgeon variability, and patient age, which have consistently 
been reported in previous trials.6,46
The risk of clinically significant (moderate and severe) 
eyelid contour abnormalities after trichiasis surgery 
was similar between treatment groups throughout the 
12 month follow­up. The risk was relatively high 
at 1 month (14% in placebo group vs 15% in doxycycline 
group), but declined to 7% in the placebo group and 
7% in the doxycycline group by 6 months and to 4% in 
the placebo group and 6% in the doxycycline group by 
12 months. Most participants who had clinically signifi­
cant eyelid contour abnormalities at 1 month had 
improvement by 6 months and 12 months: only 33% of 
participants at 6 months and 25% of participants at 
12 months still had clinically significant eyelid contour 
abnormalities. The gradual improvement in appearance 
of eyelid contour abnormalities is presumably due 
to ongoing changes within the eyelid tissues, with 
reshaping of scar tissue, which has implications for 
both patients and trachoma control programmes. Poor 
cosmetic outcome is sometimes cited as a reason to 
decline surgery, so it is encouraging that eyelid contour 
abnormalities can improve. Additionally, these results 
suggest that for all but the most severe eyelid contour 
abnormalities, in which clinically significant incomplete 
eyelid closure (lagophthalmos) might occur, repeat 
eyelid surgery might not be required since improvement 
occurs in most patients. Long­term longitudinal studies 
are required to determine the proportion of patients 
who have surgery but remain with disfiguring eyelid 
contour abnormalities and how these should be 
managed.
The factors associated with eyelid contour abnormalities 
were similar to those for postoperative trichiasis—ie, 
preoperative trichiasis severity (major trachomatous 
trichiasis), intersurgeon variability, and patient age. 
The only modifiable factor was surgeon skill, indicating 
the need for robust training programmes and ongoing 
supervision. Patients with severe trichiasis should be 
managed by the most experienced surgeons wherever 
possible.
Although doxycycline had no effect on the outcome of 
trichiasis surgery in this trial, the wider ophthalmic 
literature26–34 suggests that the drug might be beneficial 
in a number of different clinical situations. In 
ophthalmic practice, the drug is used to help promote 
healing of recurrent corneal erosions, possibly via 
anti­MMP­9 activity.47 Oral doxycycline is reported to 
improve chronic blepharitis, possibly in association with 
anti­MMP­9 activity.48 Two case reports29 of pseudomonas 
corneal melting suggest oral doxycycline helps to 
stabilise corneal breakdown via the inhibition of MMPs, 
and is widely used in clinical practice for this reason. 
Oral doxycycline was reported to be effective in inhibiting 
corneal neovascularisation and improved epithelia cell 
healing in rat corneas exposed to alkali, and is widely 
used in clinical practice for the treatment of alkali 
injuries.49
The use of doxycycline in the treatment of systemic 
conditions has had mixed results. The drug is licensed for 
use in the treatment of periodontitis; several placebo­
controlled randomised clinical trials50 have demonstrated 
that sub­antimicrobial doses can suppress MMP­mediated 
degradation of connective tissue in the periodontal 
structures. Clinical trials31 have also shown that patients 
with rosacea respond to anti­inflammatory doses of oral 
doxycycline. Several studies51 have examined whether the 
enlargement of abdominal aortic aneurysms can be 
slowed by oral doxycycline, mediated through opposing 
MMP­9 activity, but no evidence has suggested that it is 
effective for this indication. Doxycycline has also been 
proposed as a treatment in pulmonary fibrosis, although 
convincing trial data are not available at present.
In this study, treatment­associated adverse events were 
uncommon and generally mild. Adverse events were 
more frequently reported with doxycycline than placebo, 
which might explain why significantly fewer people in 
the doxycycline group were compliant when compared 
with the placebo group. The risk and type of advese 
events reported were similar to those reported in a large 
community­based trial35 of doxycycline (100 mg per day 
for 6 weeks) for onchocerciasis in Cameroon, in which 
3% of the trial participants reported nausea, vomiting, 
diarrhoea, and tiredness.
A potential limitation of this trial is the risk of 
unmasking when examiners counted the number of 
capsules left in the randomisation box to collect adherence 
data. However, we consider this highly unlikely since the 
two treatment capsules were identical.
Overall, doxycycline was found to have no effect on the 
proportion of participants who developed postoperative 
trichiasis or other unfavourable outcomes, and therefore 
is not indicated for this purpose. Preoperative disease 
characteristics, patient age, and surgeon skill seem to be 
the main determinants of outcome following trichiasis 
surgery. Trachoma control programmes and their 
partners should continue to make efforts to improve 
surgical training and supervision.
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